At the close of the deal, Altria would hold about 45% ownership interest in Cronos Group shares. Factoring in the exercise of the warrants, the total potential ownership position of Altria would be about 55%.
“This strategic partnership provides Cronos Group with additional financial resources, product development and commercialization capabilities, and deep regulatory expertise to better position the Company to compete, scale and lead the rapidly growing global cannabis industry,” read a statement by the Canadian weed company.
Cronos CEO Mike Gorenstein said, “The proceeds from Altria’s investment will enable us to more quickly expand our global infrastructure and distribution footprint, while also increasing investments in R&D and brands that resonate with our consumers.”
Under the terms of the deal, Altria has agreed to acquire 146.2 million shares of Cronos at a price of CAD16.25 per share — a 41.5% premium to Cronos’ 10-day volume weighted average price on the Toronto Stock Exchange as of Nov. 30, 2018.
The Cronos group board has unanimously backed the deal, which is expected to close in the first half of 2019.
Once the deal comes through, Altria can nominate four directors, including one independent director, to serve on the Cronos Group board, which will be expanded from five to seven directors.
The agreement also makes Altria the exclusive partner of Cronos Group “for pursuing cannabis opportunities throughout the world.” JPMorgan Chase has already given committed financing of about CAD 2.4 million to Altria for the deal.